GE Healthcare Enters Homecare Segment With Strategic Investment in Pulsenmore, Aims to Increase Peace of Mind for Expectant Mothers and Reduce In-Person Visits
May 12 2022 - 9:36AM
Business Wire
- Pulsenmore’s handheld tele-ultrasound device docks with a
smartphone, allowing women to perform ultrasound self-scans at home
and receive fast clinical feedback from healthcare
professionals
- $50m equity investment to accelerate global adoption of
technology in rapidly expanding market of homecare and telemedicine
services,
- Complementary addition to GE Healthcare’s market leading
Women’s Health & handheld ultrasound segments, aims to improve
clinical efficiency, reduce in-clinic visits, and lower healthcare
costs
GE Healthcare has entered into an agreement to invest up to $50
million in Israeli start-up Pulsenmore, marking another strategic
step forward in enabling precision health. This investment is aimed
at accelerating global adoption of Pulsenmore’s homecare ultrasound
solutions and will also support their goal to pursue U.S. FDA
clearance and commercial expansion. In addition to its equity
investment, GE Healthcare will also partner with Pulsenmore to
distribute its products in Europe and other markets as the product
becomes available for commercial distribution and collaborate
closely on developing ultrasound-based healthcare offerings that
cater to the burgeoning homecare market, which is expected to reach
USD $662.67 billion by 2027 and poised to grow at a compound annual
growth rate of 14.2%i.
The telehealth market is projected to expand at a compound
annual growth rate (CAGR) of over 30% from 2022-2029ii, creating a
need for robust technologies that can improve remote monitoring and
clinical decision-making. Pulsenmore is well positioned for this
market with its novel self-operated prenatal home ultrasound
solution, which, combined with a smartphone, enables pregnant women
to self-scan for remote clinical assessment by their healthcare
provider.
The complete product offering includes a handheld ultrasound
device that docks with the user’s smartphone; a mobile app for the
patient to conduct offline/online consultation with a clinician; a
web application for clinician-side interaction with the platform;
and a software API enabling integration of Pulsenmore’s online
services with organization health records. The periodic fetal
ultrasound scanning and consultation enabled by the Pulsenmore
device can be offered as an online clinician-guided
telecommunication service or as an offline application-guided
service.
Pulsenmore CEO and founder Dr. Elazar Sonnenschein said,
“Our agreement with GE Healthcare is a resounding vote of
confidence in our ultrasound technology and our company. With GE
Healthcare’s market leadership position and reach, we are one step
closer to achieving our vision of making home ultrasound
universally accessible for remote and reliable care, ultimately
improving maternal health across the globe. Through this exciting
partnership, we will accelerate the empowerment of women to
proactively manage their pregnancy, in collaboration with their
health care providers, and will lead the next wave of ultrasound
innovation that will benefit patients and providers alike.”
GE Healthcare Ultrasound President and CEO Roland Rott
said, “Healthcare providers are predicting a significant shift
of care services from traditional facilities to the home, which
will require an increase in the level of quality or access.
Homecare opens the door to tremendous value for payers, healthcare
facilities, physician groups and care-at-home providers, with the
opportunity to improve patients’ quality of care and experience. We
also recognize the desire of patients—in this case, pregnant
women—to be more empowered and involved in their healthcare. This
is precisely why we are investing in Pulsenmore’s innovative
homecare ultrasound technology. We are excited about adding this
highly complementary offering to our market leading Women’s Health
and Primary Care standard of care ultrasound diagnostics solutions,
marking a strong step forward in enabling precision health.”
Additional applications and devices are currently under
development by Pulsenmore, including remote follicular monitoring
for women undergoing in-vitro fertilization (IVF) as well as remote
monitoring for chronic heart failure (CHF) and end-stage renal
disease (ESRD). The Pulsenmore prenatal ultrasound platform has
already been implemented successfully across Israel in partnership
with the country’s largest HMO, Clalit Health Services. Most
recently, physicians at Israel’s Sheba Medical Center have been
using the device to conduct prenatal ultrasounds on refugees at the
Ukraine border as part of a new ‘virtual hospital’ that has Israeli
medical staff caring for people injured or displaced in the
conflict.
About GE Healthcare
GE Healthcare is the $17.7 billion healthcare business of GE
(NYSE: GE). As a leading global medical technology, pharmaceutical
diagnostics and digital solutions innovator, GE Healthcare enables
clinicians to make faster, more informed decisions through
intelligent devices, data analytics, applications, and services,
supported by its Edison intelligence platform. With over 100 years
of healthcare industry experience and around 48,000 employees
globally, the company operates at the center of an ecosystem
working toward precision health, digitizing healthcare, helping
drive productivity and improve outcomes for patients, providers,
health systems and researchers around the world.
Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights
for the latest news, or visit our website www.gehealthcare.com for
more information.
About Pulsenmore
Pulsenmore is a world leader in portable ultrasound devices for
home use and is the first to enable patients to self-scan for
remote clinical assessment. The company was founded in 2014 by its
CEO, Dr. Elazar Sonnenschein, and aims to make home ultrasound
universally accessible for remote and reliable care. The flagship
product for fetal ultrasound is approved for marketing in Europe
(CE) and in Israel. Clinical studies in the U.S. are currently
underway. Pulsenmore is traded on the Tel Aviv Stock Exchange
(TASE: PULS).
Visit our website www.pulsenmore.com for more information, or
follow us on LinkedIn for the latest news.
_________________________________ i Precedence research – Global
Home Healthcare Market 2016-2027 ii Grand View Research –
Telehealth Market Size & Share Report 2022-2028 – “CAGR of
36.8% from 2022-2029”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220512005692/en/
Nader Abou-Guendia, Global Communications Director – Ultrasound,
GE Healthcare Nader.abou-guendia@ge.com
Mira Altmark-Sofer, VP Marketing – Pulsenmore
mira@pulsenmore.com
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Mar 2024 to Apr 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Apr 2023 to Apr 2024